The China Mail - Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

USD -
AED 3.67299
AFN 71.007121
ALL 87.177673
AMD 389.933212
ANG 1.80229
AOA 916.999846
ARS 1174.273497
AUD 1.552935
AWG 1.8
AZN 1.702218
BAM 1.730107
BBD 2.023884
BDT 121.783361
BGN 1.730107
BHD 0.377903
BIF 2981.556018
BMD 1
BND 1.300632
BOB 6.926445
BRL 5.670397
BSD 1.002344
BTN 84.711398
BWP 13.647662
BYN 3.280375
BYR 19600
BZD 2.013446
CAD 1.382735
CDF 2871.00057
CHF 0.824595
CLF 0.024715
CLP 948.429675
CNY 7.2716
CNH 7.211395
COP 4268.65
CRC 506.877792
CUC 1
CUP 26.5
CVE 97.540802
CZK 22.035005
DJF 178.495289
DKK 6.59472
DOP 58.870361
DZD 132.406564
EGP 50.684198
ERN 15
ETB 134.130833
EUR 0.88371
FJD 2.255899
FKP 0.753484
GBP 0.753835
GEL 2.740386
GGP 0.753484
GHS 14.082887
GIP 0.753484
GMD 71.501466
GNF 8682.383122
GTQ 7.719935
GYD 210.323323
HKD 7.750445
HNL 26.031227
HRK 6.654501
HTG 130.824008
HUF 357.359837
IDR 16467
ILS 3.607445
IMP 0.753484
INR 84.526498
IQD 1313.105401
IRR 42112.503062
ISK 129.109797
JEP 0.753484
JMD 158.989783
JOD 0.709201
JPY 144.704962
KES 129.659667
KGS 87.450373
KHR 4016.099783
KMF 434.499971
KPW 899.999988
KRW 1399.89852
KWD 0.30664
KYD 0.835331
KZT 517.838029
LAK 21675.438984
LBP 89812.021761
LKR 300.154806
LRD 200.477686
LSL 18.451855
LTL 2.95274
LVL 0.60489
LYD 5.473042
MAD 9.29444
MDL 17.240922
MGA 4552.16949
MKD 54.429652
MMK 2099.612718
MNT 3573.127216
MOP 8.002742
MRU 39.924809
MUR 45.329866
MVR 15.410088
MWK 1738.068911
MXN 19.620915
MYR 4.2475
MZN 64.000138
NAD 18.451855
NGN 1606.869797
NIO 36.887965
NOK 10.42646
NPR 135.53806
NZD 1.681775
OMR 0.384758
PAB 1.002344
PEN 3.674908
PGK 4.155867
PHP 55.637991
PKR 281.664912
PLN 3.782845
PYG 8019.815118
QAR 3.657835
RON 4.399002
RSD 103.675527
RUB 82.845466
RWF 1414.74634
SAR 3.750206
SBD 8.340429
SCR 14.208501
SDG 600.503383
SEK 9.650075
SGD 1.297285
SHP 0.785843
SLE 22.789963
SLL 20969.483762
SOS 572.869211
SRD 36.825016
STD 20697.981008
SVC 8.770843
SYP 13001.814505
SZL 18.443982
THB 33.08991
TJS 10.374453
TMT 3.5
TND 3.00721
TOP 2.342102
TRY 38.59845
TTD 6.797293
TWD 30.719297
TZS 2699.368018
UAH 41.850767
UGX 3671.989031
UYU 42.062895
UZS 12930.249016
VES 86.73797
VND 26005
VUV 121.092148
WST 2.778527
XAF 580.261843
XAG 0.031227
XAU 0.000308
XCD 2.70255
XDR 0.72166
XOF 580.261843
XPF 105.497811
YER 244.650178
ZAR 18.420165
ZMK 9001.197777
ZMW 27.820779
ZWL 321.999592
  • CMSD

    0.0600

    22.32

    +0.27%

  • GSK

    0.3200

    39.07

    +0.82%

  • SCS

    0.2700

    10.14

    +2.66%

  • RELX

    0.9400

    55.02

    +1.71%

  • NGG

    0.0300

    71.68

    +0.04%

  • RIO

    1.1500

    59.7

    +1.93%

  • RBGPF

    67.2100

    67.21

    +100%

  • CMSC

    0.0700

    22.1

    +0.32%

  • AZN

    1.9300

    72.44

    +2.66%

  • BTI

    -0.1300

    43.17

    -0.3%

  • JRI

    0.0600

    13.07

    +0.46%

  • BCC

    3.4400

    96.15

    +3.58%

  • BCE

    0.0100

    21.45

    +0.05%

  • VOD

    -0.1200

    9.61

    -1.25%

  • RYCEF

    0.1300

    10.35

    +1.26%

  • BP

    0.2400

    28.12

    +0.85%

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 8, 2025, the Company granted 15,000 restricted stock units (RSUs) to New Employee 1, 15,000 RSUs to New Employee 2, and 45,000 RSUs to New Employee 3.

Text size:

The RSUs for New Employee 1 and New Employee 2 vest over one year starting from each employee's date of hire, and the RSUs for New Employee 3 vest equally over three years, with one-third of the shares vesting each year starting from New Employee 3's date of hire.

The RSUs for all three new employees were granted as an inducement material to each employee's acceptance of employment by the Company and were approved by the Compensation Committee of Jaguar's Board. Vesting of the RSUs is subject to each new employee's continued service with Jaguar through the applicable vesting dates.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

Contact:

[email protected]

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

Z.Huang--ThChM